Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer - Contacts and Locations

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

This study has been completed.

Study NCT00003967. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00003967

Locations


United States, Iowa
	Holden Comprehensive Cancer Center at The University of Iowa
	Iowa City, Iowa, United States, 52242-1009

United States, Maryland
	Mercy Medical Center, Inc.
	Baltimore, Maryland, United States, 21202

United States, New Jersey
	Cooper Hospital/University Medical Center
	Camden, New Jersey, United States, 08103

United States, Ohio
	Ireland Cancer Center
	Cleveland, Ohio, United States, 44106-5065
	Cleveland Clinic Taussig Cancer Center
	Cleveland, Ohio, United States, 44195
	Arthur G. James Cancer Hospital - Ohio State University
	Columbus, Ohio, United States, 43210-1240

Sponsors and Collaborators

Gynecologic Oncology Group

National Cancer Institute (NCI)

Investigators


Study Chair:	Peter G. Rose, MD	The Cleveland Clinic